633 related articles for article (PubMed ID: 22923433)
21. The mTORC1 inhibitor everolimus prevents and treats Eμ-Myc lymphoma by restoring oncogene-induced senescence.
Wall M; Poortinga G; Stanley KL; Lindemann RK; Bots M; Chan CJ; Bywater MJ; Kinross KM; Astle MV; Waldeck K; Hannan KM; Shortt J; Smyth MJ; Lowe SW; Hannan RD; Pearson RB; Johnstone RW; McArthur GA
Cancer Discov; 2013 Jan; 3(1):82-95. PubMed ID: 23242809
[TBL] [Abstract][Full Text] [Related]
22. Combination of Rapamycin and Resveratrol for Treatment of Bladder Cancer.
Alayev A; Salamon RS; Schwartz NS; Berman AY; Wiener SL; Holz MK
J Cell Physiol; 2017 Feb; 232(2):436-446. PubMed ID: 27225870
[TBL] [Abstract][Full Text] [Related]
23. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.
Weigelt B; Warne PH; Downward J
Oncogene; 2011 Jul; 30(29):3222-33. PubMed ID: 21358673
[TBL] [Abstract][Full Text] [Related]
24. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
25. Human TSC-associated renal angiomyolipoma cells are hypersensitive to ER stress.
Siroky BJ; Yin H; Babcock JT; Lu L; Hellmann AR; Dixon BP; Quilliam LA; Bissler JJ
Am J Physiol Renal Physiol; 2012 Sep; 303(6):F831-44. PubMed ID: 22791333
[TBL] [Abstract][Full Text] [Related]
26. Smooth muscle protein-22-mediated deletion of Tsc1 results in cardiac hypertrophy that is mTORC1-mediated and reversed by rapamycin.
Malhowski AJ; Hira H; Bashiruddin S; Warburton R; Goto J; Robert B; Kwiatkowski DJ; Finlay GA
Hum Mol Genet; 2011 Apr; 20(7):1290-305. PubMed ID: 21212099
[TBL] [Abstract][Full Text] [Related]
27. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
Curatolo P
Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
[TBL] [Abstract][Full Text] [Related]
28. Everolimus.
Hasskarl J
Recent Results Cancer Res; 2014; 201():373-92. PubMed ID: 24756805
[TBL] [Abstract][Full Text] [Related]
29. Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma.
Huelsmann L; Kim DNW; Hannan R; Watumull LM; Brugarolas J
Clin Genitourin Cancer; 2015 Aug; 13(4):e321-e323. PubMed ID: 25620636
[No Abstract] [Full Text] [Related]
30. The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions.
Matthew EM; Hart LS; Astrinidis A; Navaraj A; Dolloff NG; Dicker DT; Henske EP; El-Deiry WS
Cell Cycle; 2009 Dec; 8(24):4168-75. PubMed ID: 20054236
[TBL] [Abstract][Full Text] [Related]
31. TSC1 controls distribution of actin fibers through its effect on function of Rho family of small GTPases and regulates cell migration and polarity.
Ohsawa M; Kobayashi T; Okura H; Igarashi T; Mizuguchi M; Hino O
PLoS One; 2013; 8(1):e54503. PubMed ID: 23355874
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic implications of mTOR inhibitors in the treatment of gastric cancer.
Bu Z; Ji J
Curr Cancer Drug Targets; 2013 Feb; 13(2):121-5. PubMed ID: 23215721
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers.
Seront E; Rottey S; Sautois B; Kerger J; D'Hondt LA; Verschaeve V; Canon JL; Dopchie C; Vandenbulcke JM; Whenham N; Goeminne JC; Clausse M; Verhoeven D; Glorieux P; Branders S; Dupont P; Schoonjans J; Feron O; Machiels JP
Ann Oncol; 2012 Oct; 23(10):2663-2670. PubMed ID: 22473592
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of everolimus in metastatic urothelial cancer.
Smith AB; Pruthi RS
BJU Int; 2013 Aug; 112(4):427-8. PubMed ID: 23879903
[No Abstract] [Full Text] [Related]
35. Everolimus: a new hope for patients with breast cancer.
Sendur MA; Zengin N; Aksoy S; Altundag K
Curr Med Res Opin; 2014 Jan; 30(1):75-87. PubMed ID: 24050600
[TBL] [Abstract][Full Text] [Related]
36. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis.
Ozcan U; Ozcan L; Yilmaz E; Düvel K; Sahin M; Manning BD; Hotamisligil GS
Mol Cell; 2008 Mar; 29(5):541-51. PubMed ID: 18342602
[TBL] [Abstract][Full Text] [Related]
37. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
[TBL] [Abstract][Full Text] [Related]
38.
Ho DWH; Chan LK; Chiu YT; Xu IMJ; Poon RTP; Cheung TT; Tang CN; Tang VWL; Lo ILO; Lam PWY; Yau DTW; Li MX; Wong CM; Ng IOL
Gut; 2017 Aug; 66(8):1496-1506. PubMed ID: 27974549
[TBL] [Abstract][Full Text] [Related]
39. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma.
Rosich L; Xargay-Torrent S; López-Guerra M; Campo E; Colomer D; Roué G
Clin Cancer Res; 2012 Oct; 18(19):5278-89. PubMed ID: 22879389
[TBL] [Abstract][Full Text] [Related]
40. [Therapeutic update in tuberous sclerosis complex: the role of mTOR pathway inhibitors].
Ruiz-Falcó Rojas ML
Rev Neurol; 2012 May; 54 Suppl 3():S19-24. PubMed ID: 22605628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
